Zydus Lifesciences gains FDA approval for Acne treatment capsules

Zydus Lifesciences Limited has secured final approval from the US Food and Drug Administration (USFDA) for its Isotretinoin Capsules in various dosages. These capsules are designed to treat severe cystic acne, a condition unresponsive to other treatments like benzoyl peroxide or tetracycline. The approval further cements Zydus’ standing in the pharmaceutical sector, with the medication set to be manufactured at the group’s facility in Moraiya, Ahmedabad, India.

Zydus’ REMS Strategy Also Gets the Green Light

Alongside the approval for the Isotretinoin Capsules, Zydus Lifesciences has also received the nod for its Risk Evaluation and Mitigation Strategy (REMS). As mandated by Section 505-1 of the FD&C Act, the REMS program for this product includes Elements to Assure Safe Use (ETASU) and an effective implementation system. This dual approval demonstrates the company’s compliance with healthcare safety standards, especially for a drug dealing with severe medical conditions like cystic acne.

Zydus Lifesciences bags FDA approval for Acne treatment capsules. Photo courtesy of Zydus Cadila.

Isotretinoin Capsules Projected for Robust Sales

According to IQVIA MAT data as of July 2023, Isotretinoin Capsules in the specified dosages have already been responsible for annual sales totaling USD 165 million in the United States. Given this robust market, Zydus Lifesciences’ entry stands to significantly impact the pharmaceutical landscape, particularly in the acne treatment sector.

Milestone Achievement for Zydus in Drug Approvals

This latest approval marks a milestone for Zydus Lifesciences, bringing the company’s total to 378 FDA approvals. Additionally, the company has filed over 444 Abbreviated New Drug Applications (ANDAs) since the 2003-04 fiscal year. These achievements position Zydus as a major player in the pharmaceutical industry, continually expanding its diverse healthcare portfolio.

The FDA approval for Zydus Lifesciences’ Isotretinoin Capsules is a significant addition to the company’s expanding list of FDA-approved drugs. As the capsules offer a new solution for treating severe cystic acne, this move sets a precedent for the pharmaceutical industry, especially for conditions that are resistant to existing treatments. With the new approval, Zydus fortifies its reputation as a leader in healthcare solutions.